NCT03853343 is a NA clinical trial of Seaweed extract in Metabolic Syndrome, sponsored by BioAtlantis Ltd..

Who is sponsoring NCT03853343?

NCT03853343 is sponsored by BioAtlantis Ltd..

What drugs are being tested in NCT03853343?

Interventions in NCT03853343: Seaweed extract, Placebo.

What condition does NCT03853343 study?

NCT03853343 studies Metabolic Syndrome, Insulin Sensitivity.

Is NCT03853343 still recruiting?

NCT03853343 is currently completed. Last updated 2 March 2022.

Last reviewed 2022-03-02 · How we verify

NCT03853343

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Seaweed Extract Supplementation and Metabolic Biomarkers

Completed NA Last updated 2 March 2022

What this trial tests

NA trial testing Seaweed extract in Metabolic Syndrome in 10 participants. Completed in 30 January 2022.

Timeline

28 June 2018

Primary endpoint
30 January 2020

30 January 2022

Quick facts

Lead sponsor	BioAtlantis Ltd.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	10
Start date	28 June 2018
Primary completion	30 January 2020
Estimated completion	30 January 2022
Sites	1 location across United Kingdom

Drugs / interventions tested

Seaweed extract
Placebo

Conditions studied

Metabolic Syndrome — all drugs for Metabolic Syndrome →
Insulin Sensitivity — all drugs for Insulin Sensitivity →

Sponsor

BioAtlantis Ltd.

Who can join

Adults 18 to 65, any sex, with Metabolic Syndrome or Insulin Sensitivity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Double blinded, randomized, placebo controlled preliminary pilot exploratory investigation into the effects of brown seaweed extract supplementation, on fasting blood Insulin, fasting blood glucose, insulin sensitivity, blood inflammatory markers and tolerance in healthy overweight adults.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Metabolic Syndrome

Currently open trials in the same condition.

NCT07501858 — Assessing the Association Between H. Pylori Persistence and the Severity of Insulin Resistance in Patients With Metaboli · recruiting
NCT06857929 — "Improving Health and Reducing Chronic Disease Risk in Middle-Aged Adults Through Nutrition" · NA · recruiting
NCT07237750 — iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss · NA · recruiting
NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
NCT07383220 — Effect of Electrical Stimulation and Exercise on Blood Flow in Patients With Resistant High Blood Pressure · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03853343 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by BioAtlantis Ltd.
Last refreshed: 2 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03853343.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing